Northwest Bio press releases called 'inappropriate,' The Street reports Dr. Aman Buzdar of MD Anderson Cancer Center, which is running the running the DCVax-Direct phase I/II clinical trial with funding from Northwest Biotherapeutics (NWBO), called the company's press releases "extremely unusual and inappropriate," The Street's Adam Feuerstein reports, citing a phone interview. Buzdar said MD Anderson and the two other hospitals conducting the DCVAX-Direct study are yet to review or analyze the trial data since patients are still being enrolled and treated. Shares of Northwest are trading down 10% to $8.11 in pre-open trading. Reference Link
News For NWBO From The Last 14 Days
Check below for free stories on NWBO the last two weeks.